What we thought we knew may not hold up under scrutiny.
A recent JAMA Psychiatry study titled “Disorders and Paternal Use of Valproate During Spermatogenesis” has delivered surprising news:
There was no increased risk of neurodevelopmental disorders in children whose fathers were taking valproic acid around the time of conception.
This finding directly challenges earlier observational data that suggested a possible link, leading to cautionary guidance against prescribing valproate to men of reproductive age. But now, with a large, well-conducted study showing no signal of harm, we’re left reconsidering that initial recommendation.
As clinicians, we must remember:
🔍 Association is not causation.
🚧 Observational studies, while valuable, can mislead when confounding variables aren’t fully accounted for.
📚 Evidence evolves—and so must our clinical guidance.
This study not only impacts how we think about valproate use in men but also serves as a critical reminder about the limits of inference from non-randomized data.
👉 For patients with bipolar disorder or epilepsy who benefit from valproate, this offers some reassurance. We may not need to withhold an effective treatment based on unconfirmed reproductive risks.
📌 Bottom line: Always be skeptical. Always be curious. Always be willing to revise your practice when the data say it’s time.
link to the study: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2834363
